Dupixent Sales in Q4 2020
Dupixent (dupilumab), co-developed by Sanofi and Regeneron, posted global net sales of €1.3 billion in Q4 2020, up 52% from Q4 2019 at constant exchange rates. This marked its first full year above €3 billion annually, driven by expanded U.S. approvals in asthma, chronic rhinosinusitis with nasal polyps, and pediatric atopic dermatitis.1
U.S. Performance
The U.S., Dupixent's largest market, generated €919 million in Q4 sales, a 68% year-over-year increase. Atopic dermatitis remained the top indication at 57% of sales, while new asthma launches added momentum, with patient numbers growing 40% to over 100,000.1
Europe and Other Key Markets
Europe sales hit €301 million, up 22%, with strong uptake in asthma and eosinophilic esophagitis. Japan contributed €52 million, up 118%, fueled by atopic dermatitis expansion. Rest of world sales were €28 million, up 67%.1
What Drove the Growth
New indications like COPD (Phase 3 data emerging) and prurigo nodularis boosted prescriptions, with total patients exceeding 300,000 globally by year-end. Sanofi noted a 37% rise in new U.S. patients. Supply chain stability during COVID-19 helped maintain access.1
Comparison to Full-Year 2020
Q4 capped a year of €3.5 billion in global sales (up 41%), with U.S. at €2.8 billion (55% growth) and Europe at €590 million (10% growth).1
[1]: https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-04-06-00-00-2172557